Alcobra Receives Average Rating of “Buy” from Analysts (NASDAQ:ADHD)
Shares of Alcobra (NASDAQ:ADHD) have earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, AnalystRatings.Net reports. Two analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $32.29.
Shares of Alcobra (NASDAQ:ADHD) opened at 19.26 on Wednesday. Alcobra has a 52-week low of $12.29 and a 52-week high of $26.96. The stock’s 50-day moving average is $19.12 and its 200-day moving average is $18.86. The company’s market cap is $263.1 million. Alcobra also was the target of some unusual options trading activity on Thursday. Stock investors acquired 3,310 call options on the company. This is an increase of approximately 573% compared to the typical volume of 492 call options.
Alcobra (NASDAQ:ADHD) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.57) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.57). On average, analysts predict that Alcobra will post $-2.18 earnings per share for the current fiscal year.
A number of research firms have recently commented on ADHD. Analysts at FBR Capital Markets initiated coverage on shares of Alcobra in a research note on Wednesday. They set a “market perform” rating and a $23.00 price target on the stock. Separately, analysts at Piper Jaffray initiated coverage on shares of Alcobra in a research note on Monday, August 4th. They set an “overweight” rating and a $42.00 price target on the stock. Finally, analysts at Roth Capital initiated coverage on shares of Alcobra in a research note on Friday, August 1st. They set a “buy” rating and a $40.00 price target on the stock.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.